CDCA7L and COVID-19: Currently, many broad-spectrum compounds (e.g., Remdesivir, Molnupiravir, VV116, and Azvudine) have already been approved for the treatment of COVID-19 by targeting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).103–105 In addition, several candidate compounds are undergoing clinical trials that could enrich anti-COVID-19 drugs.105 Moreover, small-molecule compounds reportedly protect against SARS-CoV-2 infection by blocking the HR1-HR2 bundle assembly, paving a potential way for screening and designing broad-spectrum antiviral inhibitors.